Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel

Advances in Medical Sciences

Volumn 58, Issue 1, 2013, Pages 104-111

  Pieniazek A ^a   Czepas, J ^a   Piasecka Zelga, J ^b   Gwoadzinski K ^a   Koceva Chyla A ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

docetaxel; doxorubicin; oxidative stress; paclitaxel; rat liver

Indexed keywords

CATALASE; DOCETAXEL; DOXORUBICIN; GLUTATHIONE; PACLITAXEL; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; LIPID PEROXIDATION; LIVER; LIVER TOXICITY; MALE; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPLETION; RAT;

EID: 84886574451     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0063-1     Document Type: Article

References (59)

1. De Rossi T, Panis C, Victorino VJ, Freitas de Freitas L, da Silva do Amaral Herrera AC, Lourenço Cecchini A, Cecchini R. Breast Cancer and Oxidative Stress in Chemotherapy. Applied Cancer Research. 2009 Apr;29(4):150-6.
2. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006 Feb 16;354(7):731-9. (Pubitemid 43247143)
3. Field KM, Dow M, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008 Nov;9(11):1092-101.
4. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004 Apr;30(2):181-91. (Pubitemid 38418056)
5. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Expl Metastasis. 2008 Dec;25(2):161-9.
6. Lubgan D, Marczak A, Walczak M, Distel L, Jozwiak Z. Mechanizm dziaania doksorubicyny (DOX)-obecny stan wiedzy [Pharmacological mechanisms of Doxorubicin activity (DOX)-current state of knowledge]. Przegl Lek. 2006;63(9):782-8. Polish.
7. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, Gianni L. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res. 2001 Jun;7(6):1511-5. (Pubitemid 32708613)
8. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003 Oct;22(47):7280-95. (Pubitemid 37487160)
9. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos. 2004 Jun;32(6):666-74. (Pubitemid 38668160)
10. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007 Sep;96(9):2181-96. (Pubitemid 47477879)
11. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004 Dec;3(4):294-300. (Pubitemid 39552423)
12. Varbiro G, Veres B, Gallyas Jr F, Sumegi B. Direct effect of taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med. 2001 Aug;31(4):548-58. (Pubitemid 32728442)
13. Llesuy SF, Arnaiz SL. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology. 1990 Aug;63(2):187-98. (Pubitemid 20278682)
14. Kwiecie I, Michalska M, Wodek L. The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice. Eur J Pharmacol. 2006 Nov;21;550(1-3):39-46.
15. Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol. 2007;225:90-101. (Pubitemid 350017834)
16. Misra HP, Fridovich I. The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem. 1972 Nov;247(21):6960-2.
17. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6.
18. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70-7.
19. Rice-Evans CA, Diplock AT, Symons MCR. Techniques in free radical research. In: Burdon RH, van Knippenberg PH, editors. Laboratory Techniques in Biochemistry and Molecular Biology. Vol.
20. Amsterdam: Elsevier. 1991. p. 291.et al 20. Lowry JOH, Rosenbrough NJ, Farr RL, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265-75.
21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995 Apr;332(15):1004-14.
22. Wiseman LR, Spencer CM. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging. 1998 Apr;12(4):305-34. (Pubitemid 28181670)
23. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005 Dec;50(3):355-74.
24. Hortobagyi GN, Pivot X, Asmar L. Anthracycline-Resistant Breast Cancer. Breast Cancer. 1997 Dec 25;4(4):221-7.
25. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. (Pubitemid 41697318)
26. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999 Feb;36(2):99-114. (Pubitemid 29121684)
27. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 2009;12(1):13-6.
28. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol. 1999 Apr;10(4):391-395. (Pubitemid 29236415)
29. Zhou S, Palmeira CM, Wallace KB. Doxorubicininduced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001 May;121(3):151-7. (Pubitemid 32441771)
30. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats The effects of vitamin E and catechin. Toxicology. 2005 Apr;209(1):39-45. (Pubitemid 40269501)
31. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy. JAMA. 1991 Sep;266(12):1672-7.
32. Cao D, Qiao B, Ge Z, Yuan Y. Amplification loop cascade for increasing caspase activity induced by docetaxel. J Cell Biochem. 2005 Nov;96(4):810-20. (Pubitemid 41567551)
33. Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxelinduced cancer cell death both in vitro and in vivo. Int J Cancer. 2006 Jul;119(1):41-8.
34. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem. 2004 Dec;279(49):51057-67. (Pubitemid 40017847)
35. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem. 1999 Aug;274(32):22532-8.
36. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec;83(24):1797-805.
37. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994 Mar;86(6):441-6. (Pubitemid 24081876)
38. Hadzic T, Aykin-Burns N, Zhu Y, Coleman MC, Leick K, Jacobson GM, Spitz DR. Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radic Biol Med. 2010 Apr;48(8):1024-33.
39. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res. 2005 Sep;65(18):8455-60. (Pubitemid 41330613)
40. Powis G, Briehl M, Oblong J. Redox signalling and the control of cell growth and death. Pharmacol Ther. 1995 68(1):149-73.
41. Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxelinduced cancer cell death both in vitro and in vivo. Int J Cancer. 2006 Jul;119(1):41-8.
42. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 2007 Apr;67(8):3512-7. (Pubitemid 46762129)
43. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, Goldwasser F. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol. 2009 Apr;20(4):736-40.
44. Karaduman D, Eren B, Keles ON. The protective effect of beta-1,3-D-glucan on taxol-induced hepatotoxicity: a histopathological and stereological study. Drug Chem Toxicol. 2010 33(1):8-16.
45. Ohlmann CH, Kohlmorgen S, Sahi D, Engelmann U, Heidenreich A. Letaler Ausgang einer Chemotherapie mit Docetaxel [Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major]. Urologe A. 2007 Oct;46(10):1425-7. German. (Pubitemid 350045863)
46. Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chem Biol Interact. 2003 Oct;146(2):201-10. (Pubitemid 37323883)
47. Starenkii VP, Vasilev LYa, Nikitchenko YuV, Uzlenkova NE, Dziuba VN, Medvedeva EP, Dikii NP. [Effect of subtherapeutic doses of docetaxel (taxotere) on the efficacy of radiotherapy and pro-oxidant-antioxidant balance in rats with Guerin's carcinoma]. Radiats Biol Radioecol. 2003 Nov-Dec;43(6):640-6. Russian.
48. Durak I, Karabacak HI, Büyükkoçak S, Cimen MY, Kaçmaz M, Omeroglu E, Oztürk HS. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective effects of vitamins E and C. Nephron. 1998;78(2):207-11. (Pubitemid 28054992)
49. Yang Z, Fong DW, Yin L, Wong Y, Huang W. Liposomes modulate docetaxel-induced lipid oxidization and membrane damage in human hepatoma cells. J Liposome Res. 2009;19(2):122-30.
50. Guan X, Hoffman B, Dwivedi C, Matthees DP. A simultaneous liquid chromatography/mass spectrometric assay of glutathione, cysteine, homocysteine and their disulfides in biological samples. J Pharm Biomed Anal. 2003 Feb 26;31(2):251-61. (Pubitemid 36254807)
51. Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med. 2000 May;28(9):1405-20. (Pubitemid 30621483)
52. Wang W, Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol Rev. 1998 Sep;50(3):335-56.
53. Rothbarth J, Vahrmeijer AL, Mulder GJ. Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy. Chem Biol Interact. 2002 May;140(2):93-107. (Pubitemid 34655533)
54. Hamilton D, Fotouhi-Ardakani N, Batist G. The glutathione system in alkylator resistance. Cancer Treat Res. 2002;112:67-87.
55. Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Cancer Res. 1994 Aug;54(15):4077-83. (Pubitemid 24258112)
56. Kramer RA, Greene K, Ahmad S, Vistica DT. Chemosensitization of L-phenylalanine mustard by the thiolmodulating agent buthionine sulfoximine. Cancer Res. 1987 Mar;47(6):1593-7. (Pubitemid 17044489)
57. Medh RD, Gupta V, Awasthi YC. Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism. Biochem Pharmacol. 1991 Jul;42(2):439-41.
58. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF. Radiation survival parameters of antineoplastic drugsensitive and-resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985 May;45(5):2110-5. (Pubitemid 15024393)
59. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 1993 May;53(9):2066-70. (Pubitemid 23145727)